Zollinger‑Ellison Syndrome (Gastrinoma) – A Comprehensive Guide
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas produce excessive amounts of the hormone gastrin. Elevated gastrin stimulates the stomach lining to secrete large volumes of gastric acid, leading to severe peptic ulcer disease and related gastrointestinal problems.
Who it affects: ZES can occur at any age but most commonly presents in adults between 30 and 60 years. Both men and women are affected, with a slight male predominance (approximately 55 % male). About 25 % of cases are associated with a hereditary condition called multiple endocrine neoplasia type 1 (MEN‑1) [1].
Prevalence: The estimated incidence is 0.5–2 cases per million people per year worldwide, making it one of the rarest causes of peptic ulcer disease [2]. Because symptoms mimic more common conditions, the true prevalence may be slightly higher.
Symptoms
Gastrinomas cause a spectrum of symptoms that can be intermittent or constant. The hallmark is excess gastric acid, which leads to ulcer formation throughout the digestive tract.
Gastrointestinal Symptoms
- Refractory peptic ulcers: Ulcers that do not heal with standard therapy and may occur in atypical locations (duodenum, jejunum, colon).
- Abdominal pain: Usually epigastric, burning, or crampy; often relieved temporarily by antacids.
- Diarrhea: Occurs in 30–50 % of patients; can be watery, high‑volume, and persist despite normal diet.
- Steatorrhea (fatty stools): Result of acid inactivating pancreatic enzymes and damaging the mucosa.
- Nausea & vomiting: May be triggered by ulcer pain or severe acid reflux.
- Gastroesophageal reflux disease (GERD): Chronic heartburn caused by acid overload.
Systemic Symptoms
- Weight loss: Due to malabsorption, anorexia, and chronic diarrhea.
- Fatigue & weakness: Secondary to anemia from chronic bleeding or malnutrition.
- Iron‑deficiency anemia: Ongoing microscopic bleeding from ulcerated mucosa.
Symptoms of Associated MEN‑1 Syndrome
- Hyperparathyroidism (high calcium levels)
- Pituitary adenomas (headaches, visual changes)
- Other endocrine tumors (e.g., bronchial carcinoids)
Causes and Risk Factors
Primary cause – Gastrinoma
Gastrinomas arise from neuroendocrine cells in the pancreas, duodenum, or rarely the stomach. They are usually benign but can become malignant (approximately 30 % develop metastases, most commonly to the liver or lymph nodes) [3].
Genetic risk – MEN‑1
Individuals with a germline mutation in the MEN1 tumor suppressor gene have a 20–30 % lifetime risk of developing gastrinomas. MEN‑1 is inherited in an autosomal dominant pattern.
Other risk factors
- Family history of MEN‑1 or gastrinoma.
- Previous history of pancreatic neuroendocrine tumors.
- Chronic Helicobacter pylori infection does not cause ZES, but co‑existing infection can worsen ulcer disease.
Diagnosis
Because symptoms overlap with common acid‑related disorders, a high index of suspicion is needed, especially when ulcers are refractory or multiple.
Laboratory Tests
- Fasting serum gastrin level: A level > 1,000 pg/mL (normal < 100 pg/mL) is highly suggestive, especially when accompanied by a low gastric pH (< 2). [4]
- Secretin stimulation test: In ZES, gastrin paradoxically rises after intravenous secretin; a rise ≥ 120 pg/mL is diagnostic.
- Calcium, parathyroid hormone (PTH), and prolactin levels to screen for MEN‑1.
Imaging Studies
- Endoscopic ultrasound (EUS): Highly sensitive for small pancreatic or duodenal lesions.
- Multiphasic CT or MRI abdomen: Detects primary tumor and metastases.
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Identifies neuroendocrine tumors expressing somatostatin receptors; preferred for staging.
Endoscopic Evaluation
Upper endoscopy (EGD) visualizes ulcer disease and allows biopsy to rule out Helicobacter pylori or malignancy. In ZES, ulcers are often multiple, large (> 2 cm), and located distal to the duodenal bulb.
Diagnostic Criteria Summary
- Fasting gastrin ≥ 1,000 pg/mL OR positive secretin test.
- Evidence of gastric acid hypersecretion (pH < 2).
- Radiologic or endoscopic identification of a gastrinoma (or MEN‑1 association).
Treatment Options
Management aims to control acid hypersecretion, remove or control the tumor, and address any MEN‑1 manifestations.
Acid‑Suppressive Medications
- Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses may be 2–4 times the usual ulcer dose (e.g., omeprazole 80 mg daily) and are often required long‑term.
- Histamine‑2 receptor antagonists (H2RAs): Cimetidine or ranitidine (where available) can be adjuncts but are less effective than PPIs.
Surgical Management
- Localized gastrinoma: Enucleation or pancreaticoduodenectomy (Whipple procedure) for duodenal tumors.
- Metastatic disease: Debulking surgery, hepatic metastasectomy, or liver-directed therapies (radiofrequency ablation, transarterial chemoembolization).
- MEN‑1 patients: Surgery is individualized because tumors are often multifocal; aggressive resection may not improve survival and can increase morbidity.
Medical Therapies for Tumor Control
- Somatostatin analogs: Octreotide or lanreotide bind to somatostatin receptors, reducing gastrin secretion and sometimes shrinking tumors.
- Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are options for progressive, unresectable neuroendocrine tumors.
- Chemotherapy: Typically reserved for high‑grade or rapidly progressive disease; regimens include streptozocin‑based combos.
- Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells and has shown benefit in metastatic gastrinomas.
Lifestyle & Supportive Measures
- Small, frequent meals low in fat to lessen acid load.
- Avoidance of irritants: alcohol, nicotine, NSAIDs, and caffeine.
- Calcium and vitamin D supplementation if malabsorption or MEN‑1 hyperparathyroidism is present.
- Regular monitoring of bone density, especially in MEN‑1 patients.
Living with Zollinger‑Ellison Syndrome (gastrinoma)
Daily Management Tips
- Medication adherence: Take PPIs exactly as prescribed; many patients need twice‑daily dosing. Do not stop abruptly without physician guidance.
- Monitor symptoms: Keep a symptom diary (pain, diarrhea frequency, weight changes) to discuss with your clinician.
- Nutrition: Work with a dietitian experienced in neuroendocrine tumors. Focus on:
- High‑protein, low‑fat meals.
- Complex carbohydrates and soluble fiber to help bulk stools.
- Vitamin B‑12 and iron supplementation if labs show deficiency.
- Hydration: Replace fluids lost to diarrhea; oral rehydration solutions can prevent electrolyte imbalance.
- Regular follow‑up: At least every 3–6 months for labs (gastrin, calcium, liver function) and imaging as directed.
- Psychosocial support: Join support groups (e.g., NET Patient Network) and consider counseling to cope with chronic illness.
Vaccinations & Preventive Care
Patients on long‑term PPIs have a modestly increased risk of Clostridioides difficile infection and pneumonia; stay up‑to‑date with flu and pneumococcal vaccines.
Prevention
Because most gastrinomas arise spontaneously, primary prevention is limited. However, risk reduction strategies include:
- Genetic counseling and testing for individuals with a family history of MEN‑1.
- Screening for MEN‑1 carriers with periodic gastrin levels and abdominal imaging starting in adolescence.
- Eradication of H. pylori infection, which can exacerbate ulcer disease even though it does not cause ZES.
Complications
If left untreated or inadequately controlled, ZES can lead to serious, sometimes life‑threatening problems:
- Perforated peptic ulcer: Sudden severe abdominal pain, peritonitis, and surgical emergency.
- Gastrointestinal bleeding: Chronic blood loss causing anemia; may require endoscopic or surgical intervention.
- Severe malabsorption: Protein‑calorie deficiency, fat‑soluble vitamin deficiencies (A, D, E, K) and osteoporosis.
- Recurrent or metastatic gastrinoma: Liver metastases can impair hepatic function and cause jaundice.
- Gastric outlet obstruction: Large ulcers or tumor mass may block passage of food.
- MEN‑1 related sequelae: Hyperparathyroidism → kidney stones, osteoporosis; pituitary adenoma → vision changes.
When to Seek Emergency Care
- Sudden, severe abdominal pain that does not improve with antacids or pain medication.
- Vomiting blood (hematemesis) or passing black, tarry stools (melena) indicating gastrointestinal bleeding.
- Signs of perforation: sudden sharp pain, fever, abdominal rigidity, or swelling.
- Persistent vomiting that prevents you from keeping fluids down, leading to dehydration.
- Rapid heart rate, dizziness, fainting, or confusion – possible signs of severe blood loss or electrolyte imbalance.
- Severe, watery diarrhea (> 6 L/24 h) causing weakness, low blood pressure, or decreased urine output.
Prompt medical attention can prevent serious complications and is essential for a good outcome.
References
- Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org
- Jonkman, J. et al. “Epidemiology of gastrinomas.” Neuroendocrinology, 2016; 103(2): 89‑95. PMCID: PMC4940442
- Cleveland Clinic. Gastrinoma (Zollinger‑Ellison Syndrome). https://my.clevelandclinic.org
- NIH National Library of Medicine. “Gastrinoma (Zollinger‑Ellison Syndrome) – Diagnosis.” https://www.ncbi.nlm.nih.gov
- World Health Organization. “Neuroendocrine Tumors.” WHO Classification of Tumours, 2024.